Skip to content
Nonprofiteer
← FOUNDATION FIGHTING BLINDNESS RETINAL DEGENERATION FUND

Form 990 for tax year 2022

Filed by FOUNDATION FIGHTING BLINDNESS RETINAL DEGENERATION FUND.

Totals

Total revenue
$9,316,837
Total expenses
$1,014,874
Contributions and grants received
$14,920,274
Grants paid
$0
Program service revenue
$0
Investment income
-$5,603,437
Other revenue
$0
Total assets, end of year
$47,303,067
Total liabilities, end of year
$65,457
Net assets or fund balances, end of year
$47,237,610
Program services expenses (Part IX)
$973,431
Management and general expenses
$41,443
Fundraising expenses
$0
Program service expenses (Part III)
$973,431

Program services were 95.9% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 1d · Related organizations

    $14,920,274

  • 7a · Gross sales of assets other than inventory

    securities $303,672

  • 7b · Less cost or other basis and sales expenses

    securities $5,907,109

  • 7c · Gain or loss

    securities -$5,603,437

  • 7d · Net gain or loss

    total -$5,603,437 · excluded -$5,603,437

Functional expenses

Part IX, the statement of functional expenses.

  • 5 · Compensation of officers, directors and key employees

    total $674,390 · program services $674,390

  • 7 · Other salaries and wages

    total $28,027 · program services $28,027

  • 8 · Pension plan contributions

    total $33,987 · program services $33,987

  • 9 · Other employee benefits

    total $65,187 · program services $65,187

  • 10 · Payroll taxes

    total $43,867 · program services $43,867

  • 11a · Fees: management

    total $17,342 · program services $1,525 · management and general $15,817

  • 11b · Fees: legal

    total $48,523 · program services $32,224 · management and general $16,299

  • 11c · Fees: accounting

    total $7,823 · management and general $7,823

  • 12 · Advertising and promotion

    total $3,824 · program services $3,824

  • 13 · Office expenses

    total $6,804 · program services $6,804

  • 16 · Occupancy

    total $20,396 · program services $20,396

  • 17 · Travel

    total $27,835 · program services $27,835

  • 19 · Conferences, conventions and meetings

    total $26,560 · program services $26,560

  • 24a · Other expenses: PRINTING & PRODUCTION

    total $7,786 · program services $6,565 · management and general $1,221

  • 24e · All other expenses

    total $2,523 · program services $2,240 · management and general $283

Balance sheet

Part X, book values.

  • 1 · Cash, non-interest-bearing

    beginning of year $1,604,228 · end of year $313,572

  • 4 · Accounts receivable

    beginning of year $49,510

  • 7 · Other notes and loans receivable

    end of year $1,965,012

  • 9 · Prepaid expenses and deferred charges

    beginning of year $4,417 · end of year $6,199

  • 13 · Investments: program-related

    beginning of year $37,103,878 · end of year $37,780,078

  • 15 · Other assets

    beginning of year $6,588,060 · end of year $7,238,206

  • 17 · Accounts payable and accrued expenses

    beginning of year $65,457 · end of year $65,457

  • 25 · Other liabilities

    beginning of year $351,055 · end of year $0

  • 27 · Net assets without donor restrictions

    beginning of year $44,933,581 · end of year $47,237,610

Mission and programs · 2022

Mission

THE FOUNDATION FIGHTING BLINDNESS RETINAL DEGENERATION FUND'S MISSION IS TO ACCELERATE THE TRANSLATION OF RETINAL LABORATORY-BASED RESEARCH INTO CLINICAL TRIALS TO EXPEDITE THE COMMERCIALIZATION OF PATIENT THERAPIES.

  • THE THREE LARGEST PROGRAM SERVICES ACCOMPLISHMENTS (AS MEASURED BY EXPENSES) FOR THE FOUNDATION FIGHTING BLINDNESS RETINAL DEGENERATION FUND (FFB-RDF) DURING FISCAL 2023 WERE EQUITY INVESTMENTS IN OPUS GENETICS, PERCEIVE BIO, AND AMBER BIO. OPUS GENETICS AND PERCEIVE BIO ARE BOTH CLINICALLY STAGED GENE THERAPY COMPANIES, AND AMBER BIO IS A PRECLINICAL STAGE COMPANY. EACH OF THESE COMPANIES IS FOCUSED ON ADVANCING PROMISING THERAPIES FOR RETINAL DEGENERATIVE DISEASES.FISCAL 2023 SUMMARY:FFB-RDF INVESTED AN ADDITIONAL $7,000,000 IN OPUS GENETICS TO HELP ADVANCE ITS PIPELINE OF ORPHAN INHERITED RETINAL DISEASE INDICATIONS INCLUDING LCA5, BEST1, RDH12 AND MERTK. THE FIRST PATIENT WAS DOSED IN THE LCA5 PHASE I/II CLINICAL TRIAL IN AUGUST 2023. FFB-RDF INVESTED $2,564,098 IN PERCEIVE BIO TO HELP ADVANCE A CLINICAL-STAGE COMPLEMENT FACTOR H GENE THERAPY PROGRAM FOR THE TREATMENT OF DRY AMD, AND AN EARLY STAGED DUAL LEUCINE KINASE-DEPENDENT INHIBITOR PROGRAM AIMED AT AXONAL NEUROPROTECTION FOR THE TREATMENT OF GLAUCOMA AND RETINAL DISEASES.FFB-RDF INVESTED $1,800,000 IN AMBER BIO TO HELP SUPPORT THE DEVELOPMENT OF AN RNA EDITING PLATFORM THAT WILL BE FIRST APPLIED TO RETINAL DEGENERATIVE DISEASES.

    Expenses $973,431

As filed on the 2022 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

  • Mark Blumenkranz MD Mms

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • David Brint

    EX OFFICIO DIRECTOR

    Total calculated
    $0
    Hours/week
    1 + 10 related
  • Warren Thaler

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1 + 1 related
  • Jose-Alain Sahel MD

    DIRECTOR

    Total calculated
    $15,000
    From this org
    $0
    From related orgs
    $15,000
    Other
    $0
    Hours/week
    1 + 1 related
  • Adrienne Graves PhD

    CHAIRMAN

    Total calculated
    $0
    Hours/week
    1 + 1 related
  • Kelly Lisbakken

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Jacque Duncan MD

    EX OFFICIO DIRECTOR

    Total calculated
    $75,000
    From this org
    $0
    From related orgs
    $75,000
    Other
    $0
    Hours/week
    1 + 5 related
  • Jonathan Steinberg MD

    EX OFFICIO DIRECTOR

    Total calculated
    $0
    Hours/week
    1 + 1 related
  • Tony Adamis MD

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Jean Bennett MD PhD

    DIRECTOR

    Total calculated
    $0
    Hours/week
    1
  • Catherine Bowes Rickman PhD

    DIRECTOR

    Total calculated
    $15,000
    From this org
    $0
    From related orgs
    $15,000
    Other
    $0
    Hours/week
    1 + 1 related
  • Benjamin R Yerxa

    CEO (THRU 7/1/22)

    Total calculated
    $622,172
    From this org
    $133,821
    From related orgs
    $445,893
    Other
    $42,458
    Hours/week
    14 + 26 related

    Schedule J breakdown matched by us

    Base
    $101,576 + $386,010 related
    Bonus
    $32,049 + $59,520 related
    Other
    $196 + $363 related
    Deferred
    $1,540 + $2,860 related
    Nontaxable benefits
    $8,418 + $29,640 related
    Filer's total
    $143,779 + $478,393 related
  • Jason D Menzo

    CEO (BEG 7/1/22)

    Total calculated
    $523,027
    From this org
    $91,780
    From related orgs
    $367,118
    Other
    $64,129
    Hours/week
    8 + 32 related

    Schedule J breakdown matched by us

    Base
    $79,826 + $319,304 related
    Bonus
    $11,879 + $47,514 related
    Other
    $75 + $300 related
    Deferred
    $3,578 + $14,312 related
    Nontaxable benefits
    $9,248 + $36,991 related
    Filer's total
    $104,606 + $418,421 related
  • Peter Ginsberg

    COO

    Total calculated
    $389,133
    From this org
    $66,023
    From related orgs
    $264,095
    Other
    $59,015
    Hours/week
    8 + 32 related

    Schedule J breakdown matched by us

    Base
    $58,888 + $235,553 related
    Bonus
    $6,920 + $27,682 related
    Other
    $215 + $860 related
    Deferred
    $3,397 + $13,588 related
    Nontaxable benefits
    $8,406 + $33,624 related
    Filer's total
    $77,826 + $311,307 related
  • Russell W Kelley

    MANAGING DIRECTOR, RD FUND

    Total calculated
    $339,833
    From this org
    $280,543
    From related orgs
    $0
    Other
    $59,290
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $260,777
    Bonus
    $19,209
    Other
    $557
    Deferred
    $16,971
    Nontaxable benefits
    $42,319
    Filer's total
    $339,833

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Answered yes

  • 7 · Other non-fixed payments

Answered no

  • 4a · Severance or change-of-control payment
  • 4b · Supplemental nonqualified retirement plan
  • 4c · Equity-based compensation arrangement
  • 5a · Pay contingent on this organization's revenues
  • 5b · Pay contingent on a related organization's revenues
  • 6a · Pay contingent on this organization's net earnings
  • 6b · Pay contingent on a related organization's net earnings
  • 8 · Paid under the initial-contract exception

The filer's explanations (Part III)

PART I, LINE 7
FFB EMPLOYEES PARTICIPATE IN AN ANNUAL INCENTIVE PLAN. THE PLAN PROVIDES AN ANNUAL CASH BONUS DEPENDING UPON THE ACHIEVEMENT OF PRE-DETERMINED ORGANIZATION AND INDIVIDUAL PERFORMANCE CRITERIA.
SCHEDULE J, PART I, LINE 3:
THE FOUNDATION FIGHTING BLINDNESS, INC., A RELATED ORGANIZATION, ESTABLISHES THE COMPENSATION FOR THE ORGANIZATION'S EMPLOYEES. THE FOUNDATION FIGHTING BLINDNESS, INC. USES A COMPENSATION COMMITTEE, INDEPENDENT COMPENSATION CONSULTANT, 990 OF OTHER ORGANIZATIONS, A COMPENSATION SURVEY OR STUDY, AND APPROVAL BY THE BOARD OR COMPENSATION COMMITTEE.

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

No itemized grants to organizations on this return.

Related organizations on this return

Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.

Taxable family on this return

Schedule R Parts I, III and IV, as filed. These record ownership and control, not shared board members or money moved.

Related corporations and trusts

Part IV: related organizations taxable as a corporation or trust.

  • OPUS GENETICS INC

    C · GENE THERAPY · DE · 41.22% owned · share of income $34,580 · share of assets $1,981,206 · controlled entity

    Directly controlled by FOUNDATION FIGHTING BLINDNESS

Provenance

Return type
form_990
Tax year
2022
Filed
1 November 2023
IRS schema version
2022v5.0
Source object
202303069349302335

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.